Sabin Vaccine Institute Receives up to $6.3 Million from CEPI for Dose-Optimizing COVID-19 Vaccine Clinical Trial
May 17, 2022 15:48 ET | The Sabin Vaccine Institute
Washington, D.C., May 17, 2022 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute was awarded up to $6.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) for a clinical trial to...
Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas
May 17, 2022 07:00 ET | Nurix Therapeutics, Inc.
SAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that...
Cure Brain Cancer Foundation Invests in Innovative Clinical Trial Program to Treat Glioblastoma
May 16, 2022 06:00 ET | Cure Brain Cancer Foundation
LOS ANGELES, May 16, 2022 (GLOBE NEWSWIRE) -- This Brain Cancer Awareness Month (May), a handful of the brightest and best minds in brain cancer research will meet all around the US to discuss...
Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis
May 16, 2022 00:05 ET | Angion Biomedica Corp.
-- The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF -- Phase 1b trial to be initiated to gather tolerability, safety, and pharmacokinetic data in IPF...
IMC Logo.jpg
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™
May 09, 2022 06:00 ET | Immuron Limited
UPDATE Key Points Manufacture Completed of investigational medical products to be clinically evaluated by the Uniformed Services University (USU). The clinical program aims to determine the...
Standard BioTools Announces First Quarter 2022 Financial Results
May 05, 2022 16:02 ET | Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today...
reMYND logo 1.png
reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a
May 03, 2022 02:00 ET | reMYND
PRESS RELEASE reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a Leuven Belgium, 03 May 2022: reMYND NV, a clinical stage...
FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies
May 02, 2022 09:00 ET | Gb Sciences
LAS VEGAS, May 02, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, announces that FHI Clinical Inc. will...
Florida Cancer Specialists & Research Institute Participating in Global Clinical Trial Analyzing Patient Responsiveness to Immunotherapy Treatment
May 02, 2022 08:00 ET | Florida Cancer Specialists & Research Institute
Fort Myers, Florida, May 02, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute medical oncologist Ernesto Bustinza-Linares, MD is serving as a Principal Investigator in a...
REPEAT - 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology
May 02, 2022 08:00 ET | 180 Life Sciences Corp.
The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time points including 12 monthsThe treatment arm...